Research indicates gut inflammation reactivates dormant cancer cells in mice — Evidence Review
Published in Cell Reports, by researchers from Francis Crick Institute
Researched by
— the AI search engine for science
Table of Contents
Dormant cancer cells in bone marrow can be reactivated by inflammation elsewhere in the body, potentially leading to cancer recurrence years after initial treatment, according to new research from the Francis Crick Institute. Related studies generally support the link between inflammation and the awakening of dormant cancer cells.
- Multiple studies have shown that systemic inflammation—whether from infection, stress, or tissue injury—can trigger dormant tumor cells to exit dormancy and begin dividing, increasing the risk of metastasis and recurrence 1 2 3.
- Specific inflammatory mechanisms, such as neutrophil extracellular traps (NETs) and altered immune cell signaling, have been implicated in reactivating dormant cells and remodeling the tumor microenvironment to favor cancer growth 1 2 3 11.
- The new study adds to this evidence by identifying bone marrow changes and the HMGB2 molecule as key factors linking remote inflammation (from gut colitis) to metastatic cell reactivation, extending prior findings from lung and other tissues 1 2.
Study Overview and Key Findings
Understanding why some cancer survivors experience late relapses after years of remission is a longstanding challenge. This study explores how inflammation in distant organs—specifically the gut—can influence dormant breast cancer cells that have migrated to bone marrow, a common site for metastatic spread. By developing an innovative bone marrow model in mice, the researchers were able to directly observe how immune system activity triggered by gut inflammation could disrupt cancer cell dormancy and promote new tumor growth.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Francis Crick Institute |
| Journal Name | Cell Reports |
| Authors | Stefania Di Blasio, Tatiana Rizou, Laurie J. Gay, Nicolas Rabas, Xuanxuan Fan, Xing-Yu Liu, Victoria L. Bridgeman, Ernesto Rodriguez, Probir Chakravarty, Thomas Snoeks, Adam Karoutas, Felipe S. Rodrigues, Elodie Montaudon, Cristina Lo Celso, Elisabetta Marangoni, Dominique Bonnet, Bin-Zhi Qian, Ander Abarrategi, Ilaria Malanchi |
| Population | Mice with dormant metastatic cancer cells |
| Methods | Animal Study |
| Outcome | Reactivation of dormant cancer cells due to inflammation |
| Results | Gut inflammation increased dormant cancer cell division. |
Literature Review: Related Studies
To contextualize these findings, we searched the Consensus database, which includes over 200 million scientific papers. The following queries were used to identify relevant literature:
- gut inflammation dormant cancer cells
- cancer cell division mechanisms
- long-term cancer treatment inflammation effects
Below, we group key findings from the literature into several major topics:
| Topic | Key Findings |
|---|---|
| How does inflammation influence dormant cancer cell reactivation? | - Systemic inflammation (from infection, injury, or chronic conditions) can awaken dormant cancer cells and promote metastasis 1 2 3 11. - Inflammatory molecules, such as neutrophil extracellular traps and stress-induced proteins, have been shown to trigger dormant cell proliferation in animal models 1 2. |
| What mechanisms underlie cancer cell division and tumor reactivation? | - Disruption of cell cycle control by cancer-associated mutations leads to unchecked cell division, with reliance on alternative regulatory pathways 6 8 10. - Inflammatory signals can directly promote cell cycle re-entry and DNA replication in dormant cancer cells 1 2 3 11. |
| What is the role of the gut and microbiome in cancer and inflammation? | - Gut microbiome imbalances can drive chronic inflammation, increasing risk of colorectal and potentially systemic cancer recurrence 4 5. - Chronic gut inflammation can promote tumorigenesis and modulate immune cell responses, impacting cancer dormancy and progression 4 5. |
| How does inflammation affect long-term outcomes in cancer survivors? | - Persistent inflammation may impact long-term cancer survival and quality of life, including risk of recurrence and cognitive decline 12 14 15. - Anti-inflammatory therapies show potential to reduce recurrence risk and improve survivorship with fewer side effects than traditional chemotherapy 14. |
How does inflammation influence dormant cancer cell reactivation?
The new study’s findings align with a growing body of research demonstrating that systemic inflammation can disrupt cancer dormancy. Animal studies have shown that inflammatory events—whether from infection, injury, or other insults—can awaken dormant metastatic cells, leading to disease recurrence. Mechanisms such as neutrophil extracellular traps (NETs) and stress-induced immune proteins have been implicated in this process.
- Sustained lung inflammation in mice has been shown to awaken dormant cancer cells via NET formation, promoting aggressive metastases 1.
- Stress hormones and neutrophil activation can trigger the release of proinflammatory proteins that reactivate dormant tumor cells 2.
- Inflammatory processes in the tumor microenvironment fuel cancer progression and therapy resistance, further linking inflammation to recurrence risk 3 11.
- The new study extends these findings to the bone marrow niche and identifies a molecular mediator (HMGB2) involved in inflammation-driven awakening of dormant cells.
What mechanisms underlie cancer cell division and tumor reactivation?
Cancer cell division is tightly regulated under normal conditions, but cancer-associated mutations often disable these controls. The literature indicates that inflammation can further disrupt cell cycle control in dormant cells, encouraging them to resume proliferation.
- Mutations in cell cycle regulators allow cancer cells to continually divide, but inflammatory cues may provide additional signals for dormant cells to re-enter the cell cycle 6 8 10.
- Inflammatory signaling pathways, such as those involving cytokines and growth factors, can directly stimulate DNA replication and cell cycle progression in previously dormant cells 1 2 3 11.
- Therapies targeting the cell cycle machinery (such as CDK4/6 inhibitors) are being explored to counteract uncontrolled division and may have relevance for preventing relapse 8 10.
What is the role of the gut and microbiome in cancer and inflammation?
The gut and its resident microbiome play a crucial role in modulating systemic inflammation and cancer risk. Disruption of the gut barrier or microbiome balance can promote chronic inflammation, not only driving colorectal cancer but also potentially influencing distant cancer sites through immune signaling.
- Chronic gut inflammation is linked to cancer initiation and progression, with the microbiome shaping the immune system’s role in the tumor microenvironment 4 5.
- Microbial imbalances (dysbiosis) can hyperactivate immune cells, promote chronic inflammation, and impact anti-tumor immunity, increasing susceptibility to tumorigenesis 5.
- The new study’s demonstration that gut inflammation can reactivate dormant breast cancer cells in bone marrow highlights the potential for distant organ crosstalk via immune-mediated mechanisms.
How does inflammation affect long-term outcomes in cancer survivors?
Long-term systemic inflammation is increasingly recognized as a factor affecting survivorship, recurrence risk, and quality of life among cancer survivors. Targeting inflammation may offer new opportunities to improve outcomes.
- Elevated inflammation markers have been linked to increased recurrence risk and cognitive impairment in cancer survivors, even decades after treatment 12 15.
- Chronic inflammation can either promote or suppress cancer progression, and anti-inflammatory therapies are being explored for their potential to reduce relapse risk and improve long-term outcomes 12 14.
- Non-steroidal anti-inflammatory drugs (NSAIDs) and other agents show promise for chemoprevention with fewer side effects than traditional chemotherapy 14.
Future Research Questions
While this study advances our understanding of how inflammation can awaken dormant metastatic cancer cells, several important questions remain. Future research is needed to clarify the mechanisms in human tissues, identify biomarkers for relapse risk, and develop targeted interventions that preserve immune function while minimizing recurrence risk.
| Research Question | Relevance |
|---|---|
| Can targeting HMGB2 prevent reactivation of dormant cancer cells in humans? | Understanding whether HMGB2 inhibition can prevent relapse could inform new therapeutic strategies and help translate animal model findings to clinical practice 1 2 3. |
| What are the key immune signals that trigger cancer cell dormancy exit? | Identifying specific immune pathways involved in dormancy exit could enable precise interventions to prevent recurrence without broadly suppressing immune function 1 2 3 11. |
| How does gut microbiome composition influence reactivation of dormant cancer cells? | The gut microbiome modulates systemic inflammation and immune responses; understanding this relationship could lead to microbiome-targeted therapies to reduce recurrence 4 5. |
| Are there detectable biomarkers that predict periods of increased relapse risk in cancer survivors? | Biomarker discovery could enable individualized monitoring and early intervention during high-risk periods after remission 12 14 15. |
| What are the effects of anti-inflammatory therapies on long-term cancer recurrence and survivorship? | Evaluating the benefits and risks of anti-inflammatory drugs could optimize long-term management strategies for cancer survivors 12 14. |